Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.
P Roma, … , C R Sirtori, H B Brewer Jr
P Roma, … , C R Sirtori, H B Brewer Jr
Published April 1, 1993
Citation Information: J Clin Invest. 1993;91(4):1445-1452. https://doi.org/10.1172/JCI116349.
View: Text | PDF
Research Article Article has an altmetric score of 4

In vivo metabolism of a mutant form of apolipoprotein A-I, apo A-IMilano, associated with familial hypoalphalipoproteinemia.

  • Text
  • PDF
Abstract

Apo A-IMilano is a mutant form of apo A-I in which cysteine is substituted for arginine at amino acid 173. Subjects with apo A-IMilano are characterized by having low levels of plasma HDL cholesterol and apo A-I. To determine the kinetic etiology of the decreased plasma levels of the apo A-I in these individuals, normal and mutant apo A-I were isolated, radiolabeled with either 125I or 131I, and both types of apo A-I were simultaneously injected into two normal control subjects and two subjects heterozygous for apo A-IMilano. In the normal subjects, apo A-IMilano was catabolized more rapidly than the normal apo A-I (mean residence times of 5.11 d for normal apo A-I vs. 3.91 d for apo A-IMilano), clearly establishing that apo A-IMilano is kinetically abnormal and that it has a shortened residence time in plasma. In the two apo A-IMilano subjects, both types of apo A-I were catabolized more rapidly than normal (residence times ranging from 2.63 to 3.70 d) with normal total apo A-I production rates (mean of 10.3 vs. 10.4 mg/kg per d in the normal subjects). Therefore, in the subjects with apo A-IMilano, the decreased apo A-I levels are caused by rapid catabolism of apo A-I and not to a decreased production rate, and the abnormal apo A-IMilano leads to the rapid catabolism of both the normal and mutant forms of apo A-I in the affected subjects.

Authors

P Roma, R E Gregg, M S Meng, R Ronan, L A Zech, G Franceschini, C R Sirtori, H B Brewer Jr

×

Total citations by year

Year: 2025 2022 2021 2020 2019 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 Total
Citations: 1 1 1 3 1 1 1 2 3 6 2 3 4 2 5 2 5 1 3 3 5 4 6 5 6 8 3 4 3 1 95
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (95)

Title and authors Publication Year
HDL-replacement therapy: From traditional to emerging clinical applications
Sirtori CR, Cincotto G, Castiglione S, Pavanello C
Atherosclerosis Plus 2025
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future.
Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, Chi G, Lee JJ, Tricoci P, Kazmi SH, Fitzgerald C, Shaunik A, Berman G, Duffy D, Libby P
Current Atherosclerosis Reports 2022
Apolipoproteins in vascular biology and atherosclerotic disease
A Mehta, MD Shapiro
Nature Reviews Cardiology 2021
Lipid efflux mechanisms, relation to disease and potential therapeutic aspects
D Castaño, C Rattanasopa, VF Monteiro-Cardoso, M Corlianò, Y Liu, S Zhong, M Rusu, EA Liehn, RR Singaraja
Advanced Drug Delivery Reviews 2020
Nascent HDL (High-Density Lipoprotein) Discs Carry Cholesterol to HDL Spheres: Effects of HDL Particle Remodeling on Cholesterol Efflux
AV Navdaev, L Sborgi, SD Wright, SA Didichenko
Arteriosclerosis, thrombosis, and vascular biology 2020
Is HDL cholesterol protective in patients with type 2 diabetes? A retrospective population-based cohort study
G Fanni, R Rosato, L Gentile, M Anselmino, S Frea, V Ponzo, M Pellegrini, F Broglio, F Pivari, GM Ferrari, E Ghigo, S Bo
Journal of Translational Medicine 2020
HDL therapy today: from atherosclerosis, to stent compatibility to heart failure
CR Sirtori, M Ruscica, L Calabresi, G Chiesa, R Giovannoni, JJ Badimon
Annals of Medicine 2019
The role of paraoxonase 1 in regulating high-density lipoprotein functionality during aging
A Khalil, OK Simo, S Ikhlef, H Berrougui
Canadian Journal of Physiology and Pharmacology 2017
ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers
CL Bisgaier, R Ackermann, T Rea, WV Rodrigueza, D Hartman
Pharmacological Research 2016
ApoA-I-Directed Therapies for the Management of Atherosclerosis
JS Millar, M Cuchel
Current Atherosclerosis Reports 2015
High-density lipoprotein mimetics: promises and challenges
D Sviridov, AT Remaley
Biochemical Journal 2015
HDL quality and functionality: what can proteins and genes predict?
EA Karavia, E Zvintzou, PI Petropoulou, E Xepapadaki, C Constantinou, KE Kypreos
Expert Review of Cardiovascular Therapy 2014
A novel ApoA-I truncation (ApoA-IMytilene) associated with decreased ApoA-I production
P Anthanont, E Polisecki, BF Asztalos, MR Diffenderfer, PH Barrett, JS Millar, J Billheimer, M Cuchel, DJ Rader, EJ Schaefer
Atherosclerosis 2014
HDL and atherosclerosis: Insights from inherited HDL disorders
L Calabresi, M Gomaraschi, S Simonelli, F Bernini, G Franceschini
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2014
Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys
HJ Kempen, M Gomaraschi, SE Bellibas, S Plassmann, B Zerler, HL Collins, SJ Adelman, L Calabresi, PL Wijngaard
Journal of lipid research 2013
HDL and endothelial protection: examining evidence from HDL inherited disorders
M Gomaraschi, A Ossoli, C Vitali, L Calabresi
Clinical Lipidology 2013
Reconstituted HDL for the acute treatment of acute coronary syndrome:
BR Krause, AT Remaley
Current Opinion in Lipidology 2013
Structural basis for distinct functions of the naturally occurring Cys mutants of human apolipoprotein A-I
O Gursky, MK Jones, X Mei, JP Segrest, D Atkinson
Journal of lipid research 2013
High Density Lipoprotein: Assembly, Structure, Cargo, and Functions
AJ Murphy
ISRN Physiology 2013
Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys[S]
HJ Kempen, M Gomaraschi, SE Bellibas, S Plassmann, B Zerler, HL Collins, SJ Adelman, L Calabresi, PL Wijngaard
Journal of lipid research 2013
Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver
M Rui, W Guo, Q Ding, X Wei, J Xu, Y Xu
International Journal of Nanomedicine 2012
Lipoproteins as biosensors of endothelial oxidative status
M Farkas-Epperson, NA Le
Clinical Lipidology 2012
Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach
ML Curti, P Jacob, MC Borges, MM Rogero, SR Ferreira
Journal of Obesity 2011
Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises
TA Ahmed, I Karalis, JW Jukema
Expert Opinion on Emerging Drugs 2011
Qualitative characteristics of HDL in young patients of an acute myocardial infarction
AE Kavo, LS Rallidis, GC Sakellaropoulos, S Lehr, S Hartwig, J Eckel, PI Bozatzi, M Anastasiou-Nana, P Tsikrika, KE Kypreos
Atherosclerosis 2011
Burger's Medicinal Chemistry and Drug Discovery
S Bruno, L Ronda, S Faggiano, S Bettati, A Mozzarelli
Burger's Medicinal Chemistry and Drug Discovery 2010
HDL biogenesis and functions: Role of HDL quality and quantity in atherosclerosis
EM Tsompanidi, MS Brinkmeier, EH Fotiadou, SM Giakoumi, KE Kypreos
Atherosclerosis 2010
The HDL Handbook
NJ Hime
The HDL Handbook 2010
High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease
EJ Schaefer
2010
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I
ET Alexander, M Tanaka, M Kono, H Saito, DJ Rader, MC Phillips
Journal of lipid research 2009
Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I
ET Alexander, M Tanaka, M Kono, H Saito, DJ Rader, MC Phillips
Journal of lipid research 2009
Can We Cause Regression of Coronary Atherosclerosis?
S Alsafwah, KB Ramanathan
The American Journal of the Medical Sciences 2008
Antiatherogenic Functionality of High Density Lipoprotein: How Much versus How Gooden-subtitle=
D Sviridov, N Mukhamedova, AT Remaley, J Chin-Dusting, P Nestel
Journal of Atherosclerosis and Thrombosis 2008
ApoA‐I Milano from structure to clinical application
I Eberini, E Gianazza, L Calabresi, CR Sirtori
Annals of Medicine 2008
Therapeutic Lipidology
MH Davidson, PP Toth, KC Maki, AM Gotto
2008
Wild-type apo A-I and apo A-IMilano gene transfer reduce native and transplant arteriosclerosis to a similar extent
Y Feng, EV Craeyveld, F Jacobs, J Lievens, J Snoeys, BD Geest
Journal of Molecular Medicine 2008
Genetic determinants of HDL: monogenic disorders and contributions to variation
KL Klos, IJ Kullo
Current Opinion in Cardiology 2007
Sources of variability of plasma HDL-cholesterol levels
M Bove, AF Cicero, M Manca, I Georgoulis, R Motta, L Incorvaia, M Giovannini, G Poggiopollini, AV Gaddi
Future Lipidology 2007
Human genetics of variation in high-density lipoprotein cholesterol
A Qasim, DJ Rader
Current Atherosclerosis Reports 2006
Lipids and the endothelium: an update
AJ Murphy, D Sviridov, JP Chin-Dusting
Future Lipidology 2006
A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis
AG Rocco, L Mollica, E Gianazza, L Calabresi, G Franceschini, CR Sirtori, I Eberini
Biophysical Journal 2006
Therapeutic use of the high-density lipoprotein protein and peptides
M Marchesi, CR Sirtori
Expert Opinion on Investigational Drugs 2006
Thematic review series: Patient-Oriented Research. What have we learned about HDL metabolism from kinetics studies in humans?: Fig. 1
S Rashid, BW Patterson, GF Lewis
Journal of lipid research 2006
Properties of ApoA-I Milano
CR Sirtori
Nature Reviews Drug Discovery 2005
Introduction to risk assessment and serum risk markers for the prevention of coronary heart disease and other potential conditions that impact men's health, part II: what do I tell my patients?
MA Moyad
Urologic Clinics of North America 2004
New frontiers in atherosclerosis prevention and treatment: HDL as a novel therapeutic target
CR Sirtori
International Congress Series 2004
Apolipoprotein A-I Milano and 1-Palmitoyl-2-oleoyl Phosphatidylcholine Complex (ETC-216) Protects the in Vivo Rabbit Heart from Regional Ischemia-Reperfusion Injury
M Marchesi, EA Booth, T Davis, CL Bisgaier, BR Lucchesi
The Journal of pharmacology and experimental therapeutics 2004
Apolipoprotein A-IMilano: current perspectives
G Chiesa, CR Sirtori
Current Opinion in Lipidology 2003
Recombinant apolipoprotein A-I[Formula: See Text]: a novel agent for the induction of regression of atherosclerotic plaques
G Chiesa, CR Sirtori
Annals of Medicine 2003
High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis
DJ Rader
Journal of the American Medical Association 2003
Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-IMilano
Z Jia, P Natarajan, TM Forte, JK Bielicki
Biochemical and Biophysical Research Communications 2002
Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks
G Chiesa, E Monteggia, M Marchesi, P Lorenzon, M Laucello, V Lorusso, CD Mario, E Karvouni, RS Newton, CL Bisgaier, G Franceschini, CR Sirtori
Circulation research 2002
Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-I Milano: EVIDENCE OF APOA-I M IMPAIRED HEPATIC SECRETION
C Parolini, G Chiesa, Y Zhu, T Forte, S Caligari, E Gianazza, MG Sacco, CR Sirtori, EM Rubin
The Journal of biological chemistry 2002
Apolipoprotein A-I Milano and Apolipoprotein A-I Paris Exhibit an Antioxidant Activity Distinct from That of Wild-Type Apolipoprotein A-I
JK Bielicki, MN Oda
Biochemistry 2002
ApoA-IMALLORCA impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia
JM Martín-Campos, J Julve, JC Escolà, J Ordóñez-Llanos, J Gómez, J Binimelis, F González-Sastre, F Blanco-Vaca
Journal of lipid research 2002
Enhanced fractional catabolic rate of apo A-I and apo A-II in heterozygous subjects for apo A-IZaragoza (L144R)
D Recalde, W Velez-Carrasco, F Civeira, A Cenarro, D Gomez-Coronado, JM Ordovas, M Pocovi
Atherosclerosis 2001
Cardiovascular Status of Carriers of the Apolipoprotein A-I Milano Mutant: The Limone sul Garda Study
CR Sirtori, L Calabresi, G Franceschini, D Baldassarre, M Amato, J Johansson, M Salvetti, C Monteduro, R Zulli, ML Muiesan, E Agabiti-Rosei
Circulation 2001
Cholesterol Mobilization by Free and Lipid-Bound ApoAI Milano and ApoAI Milano −ApoAII Heterodimers
WQ Wang, AS Moses, GA Francis
Biochemistry 2001
Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL
L Calabresi, G Tedeschi, C Treu, S Ronchi, D Galbiati, S Airoldi, CR Sirtori, Y Marcel, G Franceschini
Journal of lipid research 2001
Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol
JD Kark, R Sinnreich, E Leitersdorf, Y Friedlander, S Shpitzen, G Luc
Atherosclerosis 2000
Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris
O Perez-Mendez, E Bruckert, G Franceschini, N Duhal, B Lacroix, JP Bonte, C Sirtori, JC Fruchart, G Turpin, G Luc
Atherosclerosis 2000
In Vivo Metabolism of HDL, Apo A-I, and Lp A-I, and Function of HDL -A Clinical Perspective
B Zhang, K Saku, T Ohta
Journal of Atherosclerosis and Thrombosis 2000
Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations
S Mott, L Yu, M Marcil, B Boucher, C Rondeau, J Genest Jr
Atherosclerosis 2000
Genes and Resistance to Disease
V Boulyjenkov, K Berg, Y Christen
2000
Apolipoprotein A-I: structure–function relationships
PG Frank, YL Marcel
Journal of lipid research 2000
Recombinant apolipoproteins for the treatment of vascular diseases
CR Sirtori, L Calabresi, G Franceschini
Atherosclerosis 1999
In vivo kinetics of human apolipoprotein A-I variants in rabbits
Saku, von Eckardstein, Zhang, Liu, Jimi, Ou, Ohta, Assmann, Arakawa
European Journal of Clinical Investigation 1999
A Novel Apolipoprotein A-1 Variant, Arg173Pro, Associated with Cardiac and Cutaneous Amyloidosis
KH Asl, JJ Liepnieks, M Nakamura, F Parker, MD Benson
Biochemical and Biophysical Research Communications 1999
Inhibition of arterial thrombus formation by ApoA1 Milano
D Li, S Weng, B Yang, DS Zander, T Saldeen, WW Nichols, S Khan, JL Mehta
Arteriosclerosis, thrombosis, and vascular biology 1999
A Novel Mutant, ApoA-I Nichinan (Glu235→0), Is Associated With Low HDL Cholesterol Levels and Decreased Cholesterol Efflux From Cells
H Han, J Sasaki, A Matsunaga, H Hakamata, W Huang, M Ageta, T Taguchi, T Koga, M Kugi, S Horiuchi, K Arakawa
Arteriosclerosis, thrombosis, and vascular biology 1999
Genetic influence on HDL cholesterol
DJ Betteridge, M Kahn
The Lancet 1998
Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-IMilano
G Chiesa, LJ Stoltzfus, S Michelagnoli, JK Bielicki, M Santi, TM Forte, CR Sirtori, G Franceschini, EM Rubin
Atherosclerosis 1998
Evaluation of Lipoproteins/Apolipoproteins as Therapeutic Agents for the Treatment of Vascular and Nonvascular Disease
CR Sirtori
The American Journal of Cardiology 1998
Lipoprotein-like Phospholipid Particles Inhibit the Smooth Muscle Cell Cytotoxicity of Lysophosphatidycholine and Platelet-Activating Factor
J Nilsson, B Dahlgren, M Ares, J Westman, AH Nilsson, B Cercek, PK Shah
Arteriosclerosis, thrombosis, and vascular biology 1998
A Novel Homozygous Missense Mutation in the Apo A-I Gene With Apo A-I Deficiency
W Huang, J Sasaki, A Matsunaga, H Nanimatsu, K Moriyama, H Han, M Kugi, T Koga, K Yamaguchi, K Arakawa
Arteriosclerosis, thrombosis, and vascular biology 1998
Familial HDL Deficiency Characterized by Hypercatabolism of Mature ApoA-I but Not ProApoA-I
R Batal, M Tremblay, L Krimbou, O Mamer, J Davignon, J Genest, JS Cohn
Arteriosclerosis, thrombosis, and vascular biology 1998
Apolipoprotein AI isoforms in serum determined by isoelectric focusing and immunoblotting
E Contiero, R Ferrari, GM Vaselli, M Folin
Electrophoresis 1997
In vivo metabolism of apo A-I and apo A-II in subjects with apo A-I(Lys107→0) associated with reduced HDL cholesterol and Lp(AI w AII) deficiency
M Tilly-Kiesi, CJ Packard, J Kahri, C Ehnholm, J Shepherd, MR Taskinen
Atherosclerosis 1997
The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano
E Bruckert, A Eckardstein, H Funke, I Beucler, H Wiebusch, G Turpin, G Assmann
Atherosclerosis 1997
Apolipoprotein A-I Fin: Dominantly Inherited Hypoalphalipoproteinemia Due to a Single Base Substitution in the Apolipoprotein A-I Gene
HE Miettinen, H Gylling, TA Miettinen, J Viikari, L Paulin, K Kontula
Arteriosclerosis, thrombosis, and vascular biology 1997
Subjects With ApoA-I(Lys 107 →0) Exhibit Enhanced Fractional Catabolic Rate of ApoA-I in Lp(AI) and ApoA-II in Lp(AI With AII)
M Tilly-Kiesi, AH Lichtenstein, JM Ordovas, G Dolnikowski, R Malmström, MR Taskinen, EJ Schaefer
Arteriosclerosis, thrombosis, and vascular biology 1997
Evidence That Apolipoprotein A-I Milano Has Reduced Capacity, Compared With Wild-Type Apolipoprotein A-I, to Recruit Membrane Cholesterol
JK Bielicki, MR McCall, LJ Stoltzfus, A Ravandi, A Kuksis, EM Rubin, TM Forte
Arteriosclerosis, thrombosis, and vascular biology 1997
Apolipoprotein A-I FIN (Leu159→Arg) Mutation Affects Lecithin: Cholesterol Acyltransferase Activation and Subclass Distribution of HDL but Not Cholesterol Efflux From Fibroblasts
HE Miettinen, M Jauhiainen, H Gylling, S Ehnholm, A Palomäki, TA Miettinen, K Kontula
Arteriosclerosis, thrombosis, and vascular biology 1997
Reconstituted High-Density Lipoproteins with a Disulfide-Linked Apolipoprotein A-I Dimer: Evidence for Restricted Particle Size Heterogeneity
L Calabresi, G Vecchio, F Frigerio, L Vavassori, CR Sirtori, G Franceschini
Biochemistry 1997
Human apolipoprotein A-II inhibits the formation of pre-β high density lipoproteins
L Calabresi, A Lucchini, G Vecchio, CR Sirtori, G Franceschini
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism 1996
Compound Heterozygosity for a Structural Apolipoprotein A-I Variant, Apo A-I(L141R) Pisa , and an Apolipoprotein A-I Null Allele in Patients With Absence of HDL Cholesterol, Corneal Opacifications, and Coronary Heart Disease
R Miccoli, A Bertolotto, R Navalesi, L Odoguardi, A Boni, J Wessling, H Funke, H Wiebusch, A von Eckardstein, G Assmann
Circulation 1996
Drugs Affecting Lipid Metabolism
AM Gotto, R Paoletti, LC Smith, AL Catapano, AS Jackson
1996
New targets for lipid lowering and atherosclerosis prevention
CR Sirtori
Pharmacology & Therapeutics 1995
Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia*
G Franceschini, JP Werba, AL D'Acquarica, G Gianfranceschi, S Michelagnoli, CR Sirtori
Clinical Pharmacology & Therapeutics 1995
Carboxyl-terminal Domain Truncation Alters Apolipoprotein A-I in Vivo Catabolism
HH Schmidt, AT Remaley, JA Stonik, R Ronan, A Wellmann, F Thomas, LA Zech, HB Brewer, JM Hoeg
The Journal of biological chemistry 1995
Recombinant Apolipoprotein A-I Milano Dimer Inhibits Carotid Intimal Thickening Induced by Perivascular Manipulation in Rabbits
MR Soma, E Donetti, C Parolini, CR Sirtori, R Fumagalli, G Franceschini
Circulation research 1995
Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits
S Ameli, A Hultgardh-Nilsson, B Cercek, PK Shah, JS Forrester, H Ageland, J Nilsson
Circulation 1994
In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism
K Ikewaki, DJ Rader, LA Zech, HB Brewer
Journal of lipid research 1994
Molecular characterization of native and recombinant apolipoprotein A-IMilano dimer. The introduction of an interchain disulfide bridge remarkably alters the physicochemical properties of apolipoprotein A-I
L Calabresi, G Vecchio, R Longhi, E Gianazza, G Palm, H Wadensten, A Hammarström, A Olsson, A Karlström, T Sejlitz
The Journal of biological chemistry 1994
Familial HDL deficiency due to marked hypercatabolism of normal apoA-I
J Emmerich, B Vergès, I Tauveron, D Rader, S Santamarina-Fojo, J Shaefer, M Ayrault-Jarrier, P Thiéblot, HB Brewer
Arteriosclerosis Thrombosis and Vascular Biology 1993

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 2 X users
Referenced in 1 patents
29 readers on Mendeley
See more details